Abstracts tagged "Disease Activity"

Abstract Number: 509 • 2018 ACR/ARHP Annual Meeting
Cardiovascular Disease Risk Factors May Negatively Impact Rheumatoid Arthritis Disease Outcomes: Findings from the Ontario Best Practices Research Initiative
Kathy Cui¹, Mohammad Movahedi², Claire Bombardier³ and Bindee Kuriya^4,5,6, ¹Western University, London Health Sciences Centre, London, ON, Canada, ²JSS Medical Research, St-Laurent, QC, Canada, ³Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada, ⁴Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ⁵Sinai Health System, University of Toronto, Toronto, ON, Canada, ⁶Rheumatology, University of Toronto, Toronto, ON, Canada
Background/Purpose: Rheumatoid arthritis increases the risk of cardiovascular disease (CVD). Less is known about the direct influence of CVD on RA outcomes, but higher comorbidity…
Abstract Number: 965 • 2018 ACR/ARHP Annual Meeting
Defining Cutoffs Corresponding to Low Levels of Disease Activity in Psoriatic Arthritis, Using the Patient-Reported Psoriatic Arthritis Impact of Disease Questionnaire (PsAID12). an Analysis of 436 Patients
Clémence Gorlier¹, Deborah Puyraimond-Zemmour¹, Ana-Maria Orbai², Laura C. Coates³, Uta Kiltz⁴, Ying Ying Leung⁵, Penelope Palominos⁶, Juan D. Cañete⁷, Rossana Scrivo⁸, Andra Rodica Balanescu⁹, Emmanuelle Dernis¹⁰, Sandra Tälli¹¹, Adeline Ruyssen-Witrand¹², Martin Soubrier¹³, Sibel Zehra Aydın¹⁴, Lihi Eder^15,16, Inna Gaydukova¹⁷, Ennio Lubrano¹⁸, Pascal Richette¹⁹, M. Elaine Husni²⁰, Maarten de Wit²¹, Josef S. Smolen²² and Laure Gossec²³, ¹Sorbonne Université, PARIS, France, ²Johns Hopkins University School of Medicine, Baltimore, MD, ³University of Oxford, Oxford, United Kingdom, ⁴Rheumazentrum Ruhrgebiet, Herne, Germany, ⁵Department of Rheumatology and Immunology, Singapore General Hospital, Singapore, Singapore, ⁶Rheumatology, Hospital de Clinicas de Porto Alegre, Santa Cecilia, Brazil, ⁷Rheumatology, Hospital Clinic and IDIBAPS, Barcelona, Spain, ⁸Department of Internal Medicine and Medical Specialties, Sapienza University, Rome, Italy, ⁹Department of Internal Medicine and Rheumatology “Sf. Maria” Hospital, Bucharest, Romania, ¹⁰Service de Rhumatologie, CH du Mans, Le Mans, France, ¹¹East-Tallinn Central Hospital, Department of Rheumatology, Tallinn, Estonia, ¹²Rheumatology, Purpan Hospital, Toulouse III University, Toulouse, France, ¹³Rheumatology, Department of Rheumatology, CHU Gabriel Montpied, Clermont-Ferrand, France, ¹⁴University of Ottawa, Ottawa, ON, Canada, ¹⁵Women's College Research Institute, University of Toronto, Women's College Hospital, Toronto, ON, Canada, ¹⁶Women's College Research Institute, Women's College Hospital, Toronto, ON, Canada, ¹⁷North-western state medical university n.a. II Mechnikov, St. Petersburg, Russian Federation, ¹⁸Department of Medicine and Health Sciences Vincenzo Tiberio, University of Molise, Campobasso, Italy, ¹⁹Lariboisière Hospital, Lariboisière, University of Paris 7, Paris, France, ²⁰Orthopedic and Rheumatologic Institute, Cleveland Clinic, Cleveland, OH, ²¹Dept. Medical Humanities, Amsterdam Public Health (APH), VU University Medical Centre, Amsterdam, Netherlands, ²²Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Vienna, Austria, ²³Rhumatologie, Médecine Sorbonne Université, Pitié-Salpétrière Hospital, Paris, France
Background/Purpose: The Psoriatic Arthritis (PsA) Impact of Disease questionnaire (PsAID12) score allows an assessment of patient-important symptoms and life impact in PsA. It is provisionally…
Abstract Number: 1495 • 2018 ACR/ARHP Annual Meeting
Baseline Characteristics of Methotrexate Inadequate Responder Patients with RA Who Achieved Low Disease Activity with Tofacitinib Monotherapy
Jeffrey Kaine¹, Alan J. Kivitz², Eduardo Mysler³, Noriko Iikuni⁴, Haiyun Fan⁵, Annette Diehl⁵, Jerome Paulissen⁶ and Christopher W Murray⁵, ¹Sarasota Arthritis Research Center, Sarasota, FL, ²Altoona Center for Clinical Research, Duncansville, PA, ³Organización Médica de Investigación, Buenos Aires, Argentina, ⁴Pfizer Inc, New York, NY, ⁵Pfizer Inc, Collegeville, PA, ⁶Syneos Health, Raleigh, NC
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. ORAL Strategy (NCT02187055) was a Phase 3b/4, 1-year, double-blind, triple-dummy, active comparator-controlled…
Abstract Number: 1701 • 2018 ACR/ARHP Annual Meeting
Lupus Low Disease Activity State: Predicting Organ Damage Accrual and Cardiovascular Risk in Patients with Systemic Lupus Erythematosus
Ruta Tesfamicael¹, Harrison Lam², Oria Lu², Ratushtar Kapadia¹, Caroline Siegel¹, Lori Sahakian¹, Jennifer M. Grossman^1,3 and Maureen A. McMahon^1,4, ¹University of California, Los Angeles, Los Angeles, CA, ²University of California, Los Angeles, Los angeles, CA, ³Division of Rheumatology, UCLA David Geffen School of Medicine, Los Angeles, CA, ⁴UCLA David Geffen School of Medicine, Los Angeles, CA
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a heterogeneous disease that can cause multisystem inflammation and damage. There are currently no widely agreed upon targets for…
Abstract Number: 2180 • 2018 ACR/ARHP Annual Meeting
Differences in Longitudinal Disease Activity Measures between Research Cohort and Non-Cohort Participants with Rheumatoid Arthritis Using Electronic Health Record Data
Milena Gianfrancesco¹, Laura Trupin¹, Charles McCulloch², Stephen Shiboski³, Jonathan Graf⁴, Gabriela Schmajuk⁵ and Jinoos Yazdany⁶, ¹Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, ²Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA, ³Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA, ⁴Department of Medicine, Division of Rheumatology Zuckerberg San Francisco General Hospital, University of California, San Francisco, San Francisco, CA, ⁵San Francisco VA Medical Center, San Francisco, CA, ⁶University of California, San Francisco, San Francisco, CA
Background/Purpose: Research using electronic health records (EHR) may offer advantages over traditional observational studies, including lower costs and greater generalizability to a broader patient population;…
Abstract Number: 2532 • 2018 ACR/ARHP Annual Meeting
The Efficacy and Drug Survival of the Biosimilar Infliximab (CT–P13) Compared to the Original Reference Infliximab in Inflammatory Rheumatic Diseases; Results from the Turkbio Registry
Sadettin Uslu¹, Gerçek Can¹, Soner Senel², Ediz Dalkiliç³, Nevsun Inanc⁴, Servet Akar⁵, Sinem Burcu Kocaer¹, Merih Birlik¹, Sedat Capar⁶, Nurullah Akkoc⁷ and Fatos Onen¹, ¹Rheumatology, Dokuz Eylul University Faculty of Medicine, İzmir, Turkey, ²Rheumatology, Kayseri Erciyes University, Faculty of Medicine, Kayseri, Turkey, ³Rheumatology, Uludag University Faculty of Medicine, Bursa, Turkey, ⁴Rheumatology, Marmara University, School of Medicine, Istanbul, Turkey, ⁵Rheumatology, Izmir Katip Celebi University, School of Medicine, Rheumatology, Izmir, Turkey, ⁶Dokuz Eylül University Faculty of Statistics, Izmir, Turkey, ⁷Rheumatology, İzmir, Turkey, İzmir, Turkey
Background/Purpose: Biosimilar infliximab (CT-P13) has been used to treat patients with rheumatoid arthritis (RA), ankylosing spondylitis (AS) and psoriatic arthritis (PsA) in Turkey since 2013.The…
Abstract Number: 2887 • 2018 ACR/ARHP Annual Meeting
Chronic Pain and Assessment of Pain Sensitivity in Patients with Established Axial Spondyloarthritis – a Cross-Sectional Study
Elisabeth Mogard¹, Tor Olofsson², Stefan Bergman³, Ann Bremander⁴, Lars Erik Kristensen⁵, Jack Kvistgaard Olsen⁶, Johan K Wallman⁷ and Elisabet Lindqvist⁸, ¹Department of Clinical Sciences Lund, Section of Rheumatology, Lund University, Faculty of Medicine and Skåne University Hospital, Lund, Sweden, ²Lund University, Department of Clinical Sciences Lund, Rheumatology, Lund, Sweden, Lund, Sweden, ³University of Gothenburg, Gothenburg, Sweden, ⁴Spenshult Research and Development Center, Halmstad, Sweden, ⁵Department of Rheumatology, Copenhagen University Hospital, Frederiksberg and Bispebjerg, The Parker Institute, Copenhagen, Denmark, ⁶Department of Rheumatology, Copenhagen University Hospital, Fredriksberg and Bispebjerg, The Parker Institute, Copenhagen, Denmark, ⁷Department of Clincial Sciences Lund, Rheumatology, Lund University, Lund, Sweden, ⁸Department of Clinical Sciences Lund,Section of Rheumatology, Lund University, Faculty of Medicine and Skåne University Hospital, Lund, Sweden
Background/Purpose: Pain remains a common and debilitating symptom in arthritis, despite good options to treat inflammation. In axial spondyloarthritis (axSpA), data on chronic pain remain…
Abstract Number: 9L • 2017 ACR/ARHP Annual Meeting
Circulating Type I, II and III Interferons (IFNs) Associate with IFN-Scores, but Define Distinct Subsets of Active SLE
Vilija Oke¹, Iva Gunnarsson¹, Jessica M. Dorschner², Agneta Zickert¹, Timothy B. Niewold³ and Elisabet Svenungsson¹, ¹Department of Medicine, Rheumatology Unit, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, Stockholm, Sweden, ²Division of Rheumatology and Department of Immunology, Mayo Clinic, Rochester, MN, ³Colton Center for Autoimmunity, New York University, New York, NY

Background/Purpose: Serum induced IFN gene expression (IFN-score) is considered a golden standard to assess IFN activity in SLE. So far, IFN-scores have not been compared…
Abstract Number: 471 • 2017 ACR/ARHP Annual Meeting
Rheumatoid Arthritis Patients Resistant to Biologic Therapy, Are They Different?
Adeeba Al-Herz¹, Aqeel Ghanem², Khulood Saleh³, Adel Al-Awadhi⁴, Waleed Al-Kandari³, Eman Hasan⁵, Mohammad Hussain⁵, Ibrahim Nahar², Fatemah Abutiban⁶, Ahmad Alenizi⁶, Yaser Ali², Ali Aldei¹, Hebah Alhajeri², Sawsan Hayat², Ahmad Khadrawy³, Ammad Fazal³, Khaled Mokaddem¹, Agaz Zaman², Ghada Mazloum², Youssef Bartella¹, Sally Hamed¹, Ramia Alsouk⁶ and Ahmed Al-Saber⁷, ¹Rheumatology, Al-Amiri Hospital, Kuwait city, Kuwait, ²Rheumatology, Mubarak Al-Kabeer Hospital, Hawally, Kuwait, ³Rheumatology, Farwania Hospital, Farwania, Kuwait, ⁴Faculty of Medicine, Kuwait, Kuwait, ⁵Al-Amiri Hospital, Kuwait city, Kuwait, ⁶Rheumatology, Jahra Hospital, Jahra, Kuwait, ⁷Department of Mathematics, Kuwait Technical College, Kuwait city, Kuwait
Background/Purpose: Patients with rheumatoid arthritis (RA) may fail to respond to biologic therapy. We study patients who are resistant to different classes of biologic agents…
Abstract Number: 1039 • 2017 ACR/ARHP Annual Meeting
Influences for Therapeutic Changes in Rheumatoid Arthritis Patients from the Veterans Affairs Rheumatology Arthritis Registry Who Have Moderate to High Disease Activity
Brian Sauer¹, Jacob R. Stever¹, Chia-Chen Teng, MS¹, Neil Accortt², David Collier² and Grant Cannon¹, ¹Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT, ²Amgen Inc., Thousand Oaks, CA
Background/Purpose: Current guidelines encourage the measurement of rheumatoid arthritis (RA) disease activity to achieve a low disease state (treat-to-target). Many RA patients with documented moderate…
Abstract Number: 1390 • 2017 ACR/ARHP Annual Meeting
Agreement between the DAS28-ESR and the DAS28-CRP and Factors Related to the Discrepancies between Disease Activity Levels According to These 2 Scores in Patients with Early Rheumatoid Arthritis
Cécile Gaujoux-Viala¹, Mohamed Belkacemi², Alain Cantagrel³, Bruno Fautrel⁴ and Bernard Combe⁵, ¹Rheumatology, Nîmes University Hospital and EA2415 Montpellier University, Nîmes, France, ²EA2415 Montpellier University, Montpellier, France, ³Rheumatology, Toulouse University Hospital and Toulouse University, Toulouse, France, ⁴UPMC University Paris 06, Pitié-Salpétrière Hospital, Paris, France, ⁵Rheumatology, CHU Lapeyronie and Montpellier University, Montpellier, France
Background/Purpose: DAS28 is often used as a treatment decision tool in patients with rheumatoid arthritis (RA) in the daily clinic. Although different versions of DAS28…
Abstract Number: 1692 • 2017 ACR/ARHP Annual Meeting
Decreased Lean Body Mass, Body Fat and Bone Mineral Density in Scleroderma Patients Are Associated with Disease Activity and Physical Activity
Sabina Oreska¹, Maja Spiritovic^1,2, Petr Cesak², Michal Cesak², Hana Storkanova¹, Katerina Kubinova¹, Martin Klein¹, Lucia Vernerova¹, Olga Ruzickova¹, Herman F Mann³, Karel Pavelka¹, Ladislav Senolt¹, Jiri Vencovsky¹, Radim Becvar¹ and Michal Tomcik¹, ¹Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic, ²Faculty of Physical Education and Sport, Charles University, Prague, Czech Republic, Prague, Czech Republic, ³Experimental and Clinical Rheumatology, Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic
Background/Purpose: Systemic sclerosis (SSc) is characterized by fibrosis of the skin and visceral organs, especially digestive tract, and musculoskeletal involvement, which limit mobility/self-sufficiency of patients,…
Abstract Number: 2241 • 2017 ACR/ARHP Annual Meeting
Patterns and Outcomes on Disease Activity in Patients with Ankylosing Spondylitis (AS) Using Smart System of Disease Management (SSDM): Analysis of T2T Pattern Shift and Influential Factors
Jing Xue¹, Wenqiang Fan², Hua Wei³, Jing Yang⁴, Hui Song⁵, Hongbin Li⁶, Hongzhi Wang⁷, Xinwang Duan⁸, Zhenchun Zhang⁹, Jianlin Huang¹⁰, Yasong Li¹¹, Jian Ding¹², Xiaofei Shi¹³, Miaojia Zhang¹⁴, Zhenbiao Wu¹⁵, Cundong Mi¹⁶, Fei Xiao¹⁷, Hui Xiao¹⁷, Yuhua Jia¹⁷, Rui Bai¹⁷, Yan Bu¹⁷ and Huaxiang Wu¹⁸, ¹88 Jiefang Road, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China, ²Department of rheumatology, Central Hospital of XinXiang, Henan, XinXiang, China, ³No 98,Nantong West Rd,Yangzhou, Northern Jiangsu People's Hospital, Yangzhou, China, ⁴Department of rheumatology, Central Hospital of MianYang, Sichuan, Mian Yang, China, ⁵Beijing Jishuitan Hospital, Beijing, China, ⁶The Affiliated Hospital of Inner Mongolia Medical University, Hohhot, China, ⁷The First Hospital of Jiaxing, Jiaxing, China, ⁸Department of rheumatology, The Second Affiliated Hospital of Nanchang University, Nanchang, China, ⁹People's Hospital of Linyi, Shandong, Linyi, China, ¹⁰Department of rheumatology, The Sixth Hospital Affiliated to Sun yat-sen University, Guangzhou, China, ¹¹Zhejiang Provincal People's Hospital, Hangzhou, China, ¹²Ningbo City Medical Treatment Center Lihuili Hospital, Ningbo, China, ¹³The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, China, ¹⁴Department of Rheumatology and Immunology, Jiangsu Province Hospital, Nanjing, China, ¹⁵The First Affiliated Hospital of The Fourth Military Medical University, Xi'an, China, ¹⁶The Second Affiliated Hospital of Guangxi Medical University, Nanning, China, ¹⁷Gothic Internet Technology Corporation, Shanghai, China, ¹⁸The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China
Background/Purpose: This study is to evaluate pattern shifts and outcome trends of treat-to-target (T2T) under standard of care in ankylosing spondylitis (AS) patients with interactive…
Abstract Number: 2513 • 2017 ACR/ARHP Annual Meeting
The Effect of Alcohol on Disease Activity in Axial Spondyloarthritis
Sizheng Zhao^1,2, Daniel Thong³, Stephen Duffield¹, David Hughes³ and Nicola Goodson^1,2, ¹Musculoskeletal Biology 1 Department, University of Liverpool, Liverpool, United Kingdom, ²Aintree University Hospital, Liverpool, United Kingdom, ³University of Liverpool, Liverpool, United Kingdom
Background/Purpose: There has been much interest in smoking as a modifiable risk factor for increased disease severity in rheumatic diseases. However, the effects of alcohol…
Abstract Number: 2893 • 2017 ACR/ARHP Annual Meeting
The Use of Natural Language Processing to Identify, Retrieve, Report, and Correct Observational Data on US Veterans Enrolled in the Veterans Affairs Rheumatoid Arthritis Registry
Grant Cannon¹, Jorge Rojas¹, Neill Bell², Andreas Reimold³, Ted R. Mikuls⁴, Namrata Singh⁵, Gail S. Kerr⁶, Pascale Schwab⁷, Jennifer Barton⁷, Liron Caplan⁸, Joshua Baker⁹, Angelo L. Gaffo¹⁰, J. Steuart Richards¹¹, Deana Lazaro¹², Vikas Majithia¹³ and Brian Sauer¹, ¹Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT, ²Salt Lake City VA Medical Center and University of Utah, Dallas VA Medical Center, Dallas, TX, ³Dallas VA Medical Center and University of Texas Southwestern, Dallas, TX, ⁴VA Nebraska-Western Iowa Health Care System and University of Nebraska Medical Center, Omaha, NE, ⁵VA Nebraska-Western Iowa Health Care System and University of Iowa, Omaha, IA, ⁶Washington DC VA Medical Center, Georgetown and Howard University Hospitals, Washington, DC, ⁷Portland VA Medical Center and University of Oregon, Portland, OR, ⁸Denver VA Medical Center and Univerity of Colorado, Denver, CO, ⁹Philadelphia VA Medical Center and University of Pennsylvania, Philadelphia, PR, ¹⁰Birmingham VA Medical Center and University of Alabama at Birmingham, Birmingham, AL, ¹¹Pittsburgh VA Medical Center and University Of Pittsburgh, Pittsburgh, PA, ¹²Brooklyn VA Medical Center and SUNY Downstate, Brooklyn, NY, ¹³Jackson VA Medical Center and University of Mississippi, Jackson, MS
Background/Purpose: The Veterans Affairs (VA) Rheumatoid Arthritis (RA) (VARA) registry is an observational cohort study at 12 VA medical centers that prospectively collects clinical…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].